Table 3.
Multivariable linear regression predicting cancer worry, anxiety, and depression
| Characteristic Term |
Cancer Worry Scale |
HADS-Anxiety |
HADS-Depression |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| β coefficient | 95% CI: low | 95% CI: high | P value | β coefficient | 95% CI: low | 95% CI: high | P value | β coefficient | 95% CI: low | 95% CI: high | P value | |
| Intercept | 11.835 | 9.115 | 14.555 | <.001 | 7.217 | 4.273 | 10.161 | <.001 | 4.353 | 1.797 | 6.909 | <.001 |
| Age ≥65 y | −1.236 | −2.052 | −0.42 | .003 | −1.016 | −1.899 | −0.133 | .024 | −0.821 | −1.588 | −0.054 | .036 |
| Living alone | −0.306 | −1.235 | 0.622 | .517 | 0.006 | −0.999 | 1.011 | .99 | 1.118 | 0.246 | 1.991 | .012 |
| Scheduled for nonsurgical cancer treatment | 1.124 | 0.258 | 1.99 | .011 | −0.203 | −1.138 | 0.733 | .671 | 0.409 | −0.403 | 1.222 | .322 |
| Scheduled for cancer surgery | 0.764 | −1.583 | 3.11 | .523 | −0.183 | −2.724 | 2.357 | .887 | 0.712 | −1.493 | 2.918 | .526 |
| Delay in oncology care | 0.604 | −0.184 | 1.392 | .133 | 0.947 | 0.097 | 1.797 | .029 | 0.813 | 0.075 | 1.552 | .031 |
| Medical comorbidity (noncancer) | 0.504 | −0.416 | 1.425 | .282 | 0.876 | −0.12 | 1.872 | .085 | 0.799 | −0.066 | 1.663 | .07 |
| Access to counseling (Yes vs no [referent]) | −0.786 | −1.733 | 0.162 | .104 | −0.592 | −1.612 | 0.428 | .255 | −1.148 | −2.033 | −0.262 | .011 |
| Self-described as immunocompromised (Yes vs no [referent]) | 1.705 | 0.761 | 2.649 | <.001 | 1.295 | 0.278 | 2.311 | .013 | 1.324 | 0.442 | 2.206 | .003 |
| Use of telemedicine (Yes vs no [referent]) | 0.754 | −0.226 | 1.734 | .131 | −0.324 | −1.379 | 0.731 | .546 | 0.203 | −0.713 | 1.119 | .663 |
CI, confidence interval; HADS, Hospital Anxiety and Depression Scale.
Frey et al. Ovarian cancer during the COVID-19 pandemic. Am J Obstet Gynecol 2020.